Melanoma is the leading cause of death by skin cancer in industrialized countries. Identification of tumor markers may help to define molecular pathways involved in melanoma development and progression, and identify patients with early-stage melanoma who would benefit from additional therapies. Larson et al. overview the melanoma biomarkers that are most helpful for predicting patient outcomes, and discuss the biomarkers that have demonstrated prognostic significance independent of primary tumor thickness and other common clinical prognostic indicators.
- Allison R Larson
- Eliz Konat
- Rhoda M Alani
